AbCellera Biologics Inc. ABCL Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s total liabilities & equity?
- AbCellera Biologics Inc. (ABCL) reported total liabilities & equity of $1.31B in Q1 2026.
- How has AbCellera Biologics Inc.'s total liabilities & equity changed year-over-year?
- AbCellera Biologics Inc.'s total liabilities & equity decreased by 2.8% year-over-year, from $1.34B to $1.31B.
- What is the long-term trend for AbCellera Biologics Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s total liabilities & equity has grown at a 6.2% compound annual growth rate (CAGR), from $1.01B to $1.36B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.